SCHEMBL13620758

SCHEMBL13620758

CO[C@@H]1C2OC(=O)OC2[C@H](Oc2ccc3cc(NC(C)=O)c(=O)oc3c2)OC1(C)C

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
HPGD P15428 4/20 0.53
KDM4E B2RXH2 4/20 0.53
GAA P10253 4/20 0.53
HSD17B10 Q99714 3/20 0.53
GLA P06280 3/20 0.53
CASP1 P29466 1/20 0.53
CASP7 P55210 1/20 0.53
MAOB P27338 6/20 0.46
MAOA P21397 4/20 0.46
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSP90AA1 P07900 6/20 0.39
HSP90AB1 P08238 6/20 0.39
ACHE P22303 1/20 0.38
SLC16A3 O15427 1/20 0.38
CYP2C19 P33261 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1608167 1.00 ALDH1A1 (0.53) ALDH1A1HPGDKDM4EGAAHSD17B10
SCHEMBL6936567 1.00 ALDH1A1 (0.53) ALDH1A1HPGDKDM4EGAAHSD17B10
SCHEMBL13609385 1.00 ALDH1A1 (0.53) ALDH1A1HPGDKDM4EGAAHSD17B10
SCHEMBL1608164 1.00 ALDH1A1 (0.53) ALDH1A1HPGDKDM4EGAAHSD17B10
SCHEMBL10260265 1.00 ALDH1A1 (0.53) ALDH1A1HPGDKDM4EGAAHSD17B10
SCHEMBL17049926 1.00 ALDH1A1 (0.53) ALDH1A1HPGDKDM4EGAAHSD17B10
SCHEMBL10260111 1.00 ALDH1A1 (0.53) ALDH1A1HPGDKDM4EGAAHSD17B10
SCHEMBL6931358 0.90 KDM4E (0.54) ALDH1A1HPGDKDM4EGAAHSD17B10
SCHEMBL12567077 0.89 ALDH1A1 (0.38) ALDH1A1HPGDKDM4EGAAHSD17B10
SCHEMBL10306504 0.89 ALDH1A1 (0.38) ALDH1A1HPGDKDM4EGAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622451-B2 Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders UNIVERSITY OF KANSAS (US) 2009-11-24 US disclosed